OrthoPediatrics
Logotype for OrthoPediatrics Corp

OrthoPediatrics (KIDS) investor relations material

OrthoPediatrics Stifel 2026 Healthcare Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for OrthoPediatrics Corp
Stifel 2026 Healthcare Conference 2026 summary11 Nov, 2026

Third-quarter performance and cash flow

  • Revenue grew 19% in Q3 across Trauma and Deformity, Scoliosis, international and OPSB; OPSB grew >20%, and EBITDA reached a record.

  • Management cited balanced growth and strong legacy-product pull-through alongside new-product contributions.

  • Q3 generated positive free cash flow; management expects at least $6M in Q4 and reiterated its 2026 FCF break-even goal, after $10M positive FCF in Q4 last year.

Near-term outlook and international growth

  • Q4 is typically seasonally weaker than Q2 and Q3; management expects to guide conservatively after a robust summer.

  • 7D sales remain excluded from most guidance due to uncertain timing; Latin America set sales are being limited to support AR and prioritize profitable sales and FCF.

  • International replenishment demand is growing faster than reported results suggest, amid Brazil and LATAM headwinds and tough set-sale comps.

  • EU MDR approvals are enabling early launches of established U.S. products in Europe; the Super Cycle is not yet reflected in international forecasts for 2027.

Product cycle and growth runway

  • Super Cycle products primarily add indications and case coverage rather than replace existing products, opening new pediatric treatment opportunities.

  • 3P Hip is ahead of plan, contributed in Q3, and is expected to add more in Q4 and H1 2027 as more sets are deployed; 3P Small Mini is in limited release.

  • 3P Small Mini is expected to progress toward full market release in 2027; 3P Femur and additional systems are planned for H2 2027 and 2028.

  • Management expects Super Cycle products to contribute a larger share of sales in 2027–2028 and beyond, with generally higher ASPs, better margins and improved capital utilization.

  • eLLi IDE approval is expected hopefully in early 2027, followed by first cases; full approval timing depends on FDA requirements for patient follow-up.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next OrthoPediatrics earnings date

Logotype for OrthoPediatrics Corp
38th Annual Healthcare Conference2 Dec, 2026
OrthoPediatrics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next OrthoPediatrics earnings date

Logotype for OrthoPediatrics Corp
38th Annual Healthcare Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

OrthoPediatrics Corp. is a medical device company specializing in the design and manufacture of orthopedic solutions for pediatric patients. The company’s product portfolio includes implants, surgical instruments, and biologics to address conditions such as scoliosis, trauma, and deformities. OrthoPediatrics collaborates with surgeons to develop specialized systems tailored to the unique needs of children and adolescents. The company is headquartered in Warsaw, Indiana, and its shares are listed on the NASDAQ.